High-dose inactivated influenza vaccine (HD-IIV) significantly reduces the risk of cardiorespiratory and cardiovascular hospitalizations compared to standard-dose (SD-IIV) in adults 65 years and older.
The benefits of HD-IIV are consistent across patients with and without diabetes, supporting broad clinical utility.
Subgroup analysis reveals that older adults with a diabetes duration of over 5 years may derive even greater cardiorespiratory protection from HD-IIV (rVE 20.4%).
The findings reinforce the role of vaccination as a critical secondary prevention strategy for cardiovascular events in high-risk metabolic populations.
